

# Bruce D Cheson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2038669/publications.pdf>

Version: 2024-02-01

348  
papers

39,014  
citations

17776

65  
h-index

3100

193  
g-index

357  
all docs

357  
docs citations

357  
times ranked

24742  
citing authors

#	ARTICLE	IF	CITATIONS
1	Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials. <i>Journal of Clinical Oncology</i> , 2023, 41, 336-342.	0.8	9
2	Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial. <i>Cancer Medicine</i> , 2022, 11, 61-73.	1.3	4
3	Anti-CD79B Antibody-Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study. <i>Clinical Cancer Research</i> , 2022, 28, 1294-1301.	3.2	12
4	Value of assessing liver enlargement as a group a parameter in chronic lymphocytic leukemia (CLL) clinical trials: Retrospective review of data from multiple trials for incidence of liver enlargement and impact on response assessment.. <i>Journal of Clinical Oncology</i> , 2022, 40, e19517-e19517.	0.8	0
5	Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3K $\gamma$ inhibitor therapy. <i>Blood</i> , 2021, 137, 2817-2826.	0.6	38
6	Copanlisib in the Treatment of Relapsed Follicular Lymphoma: Utility and Experience from the Clinic. <i>Cancer Management and Research</i> , 2021, Volume 13, 677-692.	0.9	10
7	Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. <i>Haematologica</i> , 2021, 106, 2364-2373.	1.7	53
8	Diffuse large B-cell lymphoma: new targets and novel therapies. <i>Blood Cancer Journal</i> , 2021, 11, 68.	2.8	41
9	Umbralisib, a Dual PI3K $\gamma$ /CK1 $\beta$ Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1609-1618.	0.8	111
10	CALGB 50801 (Alliance): PET adapted therapy in bulky stage I/II classic Hodgkin lymphoma (cHL).. <i>Journal of Clinical Oncology</i> , 2021, 39, 7507-7507.	0.8	7
11	Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2021, Volume 11, 55-66.	1.2	2
12	Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy. <i>American Journal of Surgical Pathology</i> , 2021, 45, 384-393.	2.1	10
13	Current Role of Functional Imaging in the Management of Lymphoma. <i>Current Oncology Reports</i> , 2021, 23, 144.	1.8	11
14	MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial. <i>Leukemia</i> , 2020, 34, 522-532.	3.3	26
15	The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2020, 188, 918-923.	1.2	19
16	Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. <i>Lancet Haematology</i> , 2020, 7, e112-e121.	2.2	119
17	Copanlisib in the treatment of non-Hodgkin lymphoma. <i>Future Oncology</i> , 2020, 16, 1947-1955.	1.1	11
18	<p>The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy</p>. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2020, Volume 10, 1-5.	1.2	1

#	ARTICLE	IF	CITATIONS
19	Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial. <i>Blood</i> , 2020, 135, 2224-2234.	0.6	62
20	Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial. <i>Haematologica</i> , 2020, 105, e519.	1.7	8
21	Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. <i>Clinical Cancer Research</i> , 2020, 26, 3589-3596.	3.2	80
22	Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: <scp>CALGB</scp>/Alliance 50403. <i>American Journal of Hematology</i> , 2020, 95, 583-593.	2.0	18
23	Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia. <i>Haematologica</i> , 2020, 106, 284-287.	1.7	8
24	Successful Treatment of Ocular Chronic Lymphocytic Leukemia with Ibrutinib: Case Report and Review of the Literature. <i>Leukemia Research Reports</i> , 2020, 14, 100200.	0.2	1
25	Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1414-1424.	2.0	5
26	Management of Adverse Events From the Combination of Rituximab and Lenalidomide in the Treatment of Patients With Follicular and Low-Grade Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 563-571.	0.2	10
27	Umbralisib, the Once Daily Dual Inhibitor of PI3K $\hat{\nu}$ and Casein Kinase-1 $\hat{\mu}$ Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global Unity-NHL Trial. <i>Blood</i> , 2020, 136, 34-35.	0.6	8
28	Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma. <i>Blood</i> , 2020, 136, 46-47.	0.6	6
29	Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study. <i>Blood</i> , 2020, 136, 46-47.	0.6	12
30	Ongoing, first-in-human, phase I dose escalation study of the investigational CD47-blocker TTI-622 in patients with advanced relapsed or refractory lymphoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3030-3030.	0.8	6
31	Phase II, multicenter trial of nivolumab (Nivo) and brentuximab vedotin (BV) in patients (Pts) with untreated Hodgkin lymphoma (HL) over the age of 60 years or unable to receive standard ABVD chemotherapy: Results of a study of Academic and Community Cancer Research United (ACCRU) RU0515051.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8014-8014.	0.8	3
32	Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of induction therapy in Alliance 51101.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8042-8042.	0.8	4
33	Relevance of bone marrow biopsies for response assessment in NCTN follicular lymphoma clinical trials.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8038-8038.	0.8	1
34	Functional Imaging in Hodgkin Lymphoma. <i>Hematologic Malignancies</i> , 2020, , 113-143.	0.2	0
35	Targeting Biology in Non-Hodgkin Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 727-738.	0.9	1
36	Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance). <i>Cancer</i> , 2019, 125, 3378-3389.	2.0	10

#	ARTICLE	IF	CITATIONS
37	Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2019, 37, 1391-1402.	0.8	177
38	Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. <i>Clinical Cancer Research</i> , 2019, 25, 4264-4270.	3.2	61
39	Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). <i>Lancet Haematology</i> , 2019, 6, e254-e265.	2.2	184
40	Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. <i>Journal of Clinical Oncology</i> , 2019, 37, 1790-1799.	0.8	266
41	Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy. <i>Haematologica</i> , 2019, 104, 2258-2264.	1.7	26
42	Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance). <i>British Journal of Haematology</i> , 2019, 185, 53-64.	1.2	9
43	A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. <i>Blood Advances</i> , 2019, 3, 1568-1573.	2.5	26
44	Introduction by the Guest Editor. <i>Cancer Journal (Sudbury, Mass)</i> , 2019, 25, 373-373.	1.0	0
45	Targeted Therapies in Chronic Lymphocytic Leukemia. <i>Cancer Journal (Sudbury, Mass)</i> , 2019, 25, 449-454.	1.0	1
46	The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials. <i>Cancer Medicine</i> , 2019, 8, 165-173.	1.3	27
47	Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor. <i>British Journal of Haematology</i> , 2019, 185, 961-966.	1.2	12
48	Combinations or sequences of targeted agents in CLL: is the whole greater than the sum of its parts (Aristotle, 360 BC)? <i>Blood</i> , 2019, 133, 121-129.	0.6	18
49	Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 135-141.	0.2	37
50	Descriptive analysis of genetic aberrations and cell of origin in Richter transformation. <i>Leukemia and Lymphoma</i> , 2019, 60, 971-979.	0.6	3
51	Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study. <i>Blood</i> , 2019, 134, 2874-2874.	0.6	19
52	Sustained Overall Survival Benefit of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Maintenance Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Final Results of the GadoIn Study. <i>Blood</i> , 2019, 134, 2822-2822.	0.6	3
53	Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies. <i>Blood</i> , 2019, 134, 502-502.	0.6	4
54	Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies. <i>Blood</i> , 2019, 134, 1756-1756.	0.6	1

#	ARTICLE	IF	CITATIONS
55	A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: The First-Mind Trial. <i>Blood</i> , 2019, 134, 2877-2877.	0.6	3
56	Toxicities and Outcomes of Acalabrutinib-Treated Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients. <i>Blood</i> , 2019, 134, 4311-4311.	0.6	15
57	Phase 1/2 trial of acalabrutinib plus pembrolizumab (Pem) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2019, 37, 7519-7519.	0.8	9
58	Phase 2 study of acalabrutinib in ibrutinib (IBR)-intolerant patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).. <i>Journal of Clinical Oncology</i> , 2019, 37, 7530-7530.	0.8	9
59	Long-Term Follow-up of Follicular Lymphoma (FL) Patients (pts) Demonstrating Undetectable Minimal Residual Disease (MRD) Using a Next-Generation Based DNA Assay: Support for FL As a Curable Disease. <i>Blood</i> , 2019, 134, 2813-2813.	0.6	0
60	North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 1553-1553.	0.6	0
61	Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study. <i>Blood</i> , 2019, 134, 3048-3048.	0.6	0
62	Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611). <i>Journal of Geriatric Oncology</i> , 2018, 9, 321-328.	0.5	5
63	Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. <i>Haematologica</i> , 2018, 103, 874-879.	1.7	329
64	iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. <i>Blood</i> , 2018, 131, 2745-2760.	0.6	1,069
65	PET/CT in Lymphoma: Current Overview and Future Directions. <i>Seminars in Nuclear Medicine</i> , 2018, 48, 76-81.	2.5	57
66	Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 65-75.	5.1	314
67	Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus <sup>131</sup> I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016. <i>Journal of Clinical Oncology</i> , 2018, 36, 697-703.	0.8	68
68	Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 2259-2266.	0.8	107
69	Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 2405-2412.	0.8	81
70	A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL. <i>Blood Advances</i> , 2018, 2, 762-768.	2.5	19
71	CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. <i>Blood</i> , 2018, 132, 1013-1021.	0.6	90
72	Surrogate Endpoints and Risk Adaptive Strategies in Previously Untreated Follicular Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 447-451.	0.2	3

#	ARTICLE	IF	CITATIONS
73	Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. American Journal of Hematology, 2018, 93, 1394-1401.	2.0	52
74	Determining the sequence of novel therapies in the treatment of relapsed Hodgkin's lymphoma. Expert Review of Hematology, 2018, 11, 773-780.	1.0	1
75	Speaking volumes about volumes. Blood, 2018, 131, 2408-2409.	0.6	1
76	Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica, 2018, 103, 1511-1517.	1.7	135
77	Bortezomib Maintenance (BM) or Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): 8 Year Follow up of CALGB 50403 (Alliance). Blood, 2018, 132, 146-146.	0.6	6
78	Venetoclax As Monotherapy or in Combination: Patterns of Use and Predictors of Outcomes in an International Multicenter Study of CLL Patients. Blood, 2018, 132, 3142-3142.	0.6	2
79	Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Primary Analysis of a Phase I/II Study. Blood, 2018, 132, 2969-2969.	0.6	9
80	The dual SYK/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2 study in patients with relapsed/refractory B- and T-cell non-Hodgkin lymphoma (NHL).. Journal of Clinical Oncology, 2018, 36, 7511-7511.	0.8	6
81	A phase 2 study to assess the safety and efficacy of umbralisib (TGR-1202) in pts with CLL who are intolerant to prior BTK or PI3K $\gamma$ inhibitor therapy.. Journal of Clinical Oncology, 2018, 36, 7530-7530.	0.8	5
82	Racial, age, and sex disparities in chronic lymphocytic leukemia (CLL) patients treated with novel therapies.. Journal of Clinical Oncology, 2018, 36, 6577-6577.	0.8	0
83	A U.S.-based survey: The experiences of 1147 chronic lymphocytic leukemia (CLL) patients (pts).. Journal of Clinical Oncology, 2018, 36, 7532-7532.	0.8	1
84	Adverse Events, Patterns of Tumor Lysis Syndrome Prophylaxis and Management, and Dosing Patterns in a Large Cohort of Venetoclax Treated CLL Patients in Community and Academic Settings. Blood, 2018, 132, 4410-4410.	0.6	0
85	Factors That Influence Treatment Decision-Making: Perspectives of 1147 Chronic Lymphocytic Leukemia (CLL) Patients in the United States. Blood, 2018, 132, 4414-4414.	0.6	1
86	Identification of a Genetic Signature Enriching for Response to Ibrutinib in Relapsed/Refractory Follicular Lymphoma in the Dawn Phase 2 Trial. Blood, 2018, 132, 4147-4147.	0.6	0
87	Recommendations for Clinical Trial Development in Follicular Lymphoma. Journal of the National Cancer Institute, 2017, 109, djw255.	3.0	23
88	Overestimated value of $^{18}\text{F}$ -FDG based bone marrow evaluation in lymphoma: Response to Adams and Kwee. British Journal of Haematology, 2017, 179, 337-339.	1.2	1
89	Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma. British Journal of Haematology, 2017, 178, 250-256.	1.2	30
90	Pros and cons of rituximab maintenance in follicular lymphoma. Cancer Treatment Reviews, 2017, 58, 34-40.	3.4	8

#	ARTICLE	IF	CITATIONS
91	Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. <i>Lancet Haematology</i> , 2017, 4, e176-e182.	2.2	77
92	Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone. <i>Annals of Hematology</i> , 2017, 96, 253-259.	0.8	22
93	but not HCVAD is a feasible induction regimen prior to autoantigen HCT in frontline MCL: results of SWOG Study S1106. <i>British Journal of Haematology</i> , 2017, 176, 759-769.	1.2	40
94	Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793); Tj ETQq0 006gBT /Overlock 10		
95	Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents. <i>Oncologist</i> , 2017, 22, 1283-1291.	1.9	53
96	What Is the Role of Chemotherapy in Patients With Chronic Lymphocytic Leukemia?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 723-727.	0.2	4
97	Extended Follow-up of Patients Treated With Bendamustine for Lymphoid Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 637-644.	0.2	14
98	Investigator and independent review committee exploratory assessment and verification of tumor response in a non-Hodgkin lymphoma study. <i>Leukemia and Lymphoma</i> , 2017, 58, 1332-1340.	0.6	3
99	Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2017, 23, 1167-1176.	3.2	77
100	Impact of obinutuzumab alone and in combination for follicular lymphoma. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2017, Volume 7, 73-83.	1.2	1
101	Analysis of PET-CT to Identify Richter's Transformation in 167 Patients with Disease Progression Following Kinase Inhibitor Therapy. <i>Blood</i> , 2017, 130, 834-834.	0.6	11
102	Evidence of low incidence of myelodysplastic syndrome (MDS) in patients exposed to bendamustine treatment for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).. <i>Journal of Clinical Oncology</i> , 2017, 35, e19008-e19008.	0.8	3
103	KI intolerance study: A phase 2 study to assess the safety and efficacy of TGR-1202 in pts with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K-delta inhibitor therapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS7569-TPS7569.	0.8	0
104	Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. <i>Blood</i> , 2016, 128, 2199-2205.	0.6	166
105	Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103. <i>Blood</i> , 2016, 128, 2510-2516.	0.6	56
106	US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. <i>Journal of Clinical Oncology</i> , 2016, 34, 2020-2027.	0.8	239
107	Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. <i>Blood</i> , 2016, 127, 2411-2415.	0.6	131
108	Speed bumps on the road to a chemotherapy-free world for lymphoma patients. <i>Blood</i> , 2016, 128, 325-330.	0.6	17

#	ARTICLE	IF	CITATIONS
109	Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. <i>Blood</i> , 2016, 128, 2489-2496.	0.6	370
110	PI3K signaling pathway in normal B cells and indolent B-cell malignancies. <i>Seminars in Oncology</i> , 2016, 43, 647-654.	0.8	31
111	Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1081-1093.	5.1	297
112	The role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemia. <i>Therapeutic Advances in Hematology</i> , 2016, 7, 69-84.	1.1	23
113	<sup>18</sup> F- <sup>18</sup> F- <sup>18</sup> F-FDG PET-CT and trephine biopsy assessment of bone marrow involvement in lymphoma. <i>British Journal of Haematology</i> , 2016, 174, 410-416.	1.2	30
114	Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel – an update. <i>Leukemia and Lymphoma</i> , 2016, 57, 766-782.	0.6	70
115	Early Relapse of Follicular Lymphoma after Rituximab-Based Biologic Doublet Upfront Therapy Is Associated with Increased Risk of Death: A Combined Analysis from CALGB Studies 50402, 50701 and 50803 (Alliance). <i>Blood</i> , 2016, 128, 2953-2953.	0.6	3
116	Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of GS-4059 in Combination with Idelalisib in Subjects with B-Cell Malignancies. <i>Blood</i> , 2016, 128, 2961-2961.	0.6	1
117	Pseudo-Progression Among Patients with Follicular Lymphoma Treated with Ibrutinib in the Phase 2 DAWN Study. <i>Blood</i> , 2016, 128, 2980-2980.	0.6	3
118	Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial. <i>Blood</i> , 2016, 128, 2992-2992.	0.6	5
119	Toxicities and Outcomes of Ibrutinib-Treated Patients in the United States: Large Retrospective Analysis of 621 Real World Patients. <i>Blood</i> , 2016, 128, 3222-3222.	0.6	16
120	Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in CLL: Results from a Large Multi-Center Study of 683 US-Patients. <i>Blood</i> , 2016, 128, 4400-4400.	0.6	2
121	Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303. <i>Blood</i> , 2016, 128, 469-469.	0.6	79
122	Toxicities and Related Outcomes of Elderly Patients (pts) (>=65 Years) with Hematologic Malignancies in the Contemporary Era (Alliance A151611). <i>Blood</i> , 2016, 128, 536-536.	0.6	1
123	Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study. <i>Blood</i> , 2016, 128, 615-615.	0.6	22
124	Continued Excellent Outcomes in Previously Untreated Follicular Lymphoma Patients after Treatment with CHOP Plus Rituximab or CHOP Plus (131) Iodine-Tositumomab - Long Term Follow-up of Phase III Randomized Study SWOG S0016. <i>Blood</i> , 2016, 128, 616-616.	0.6	3
125	Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or Idelalisib. <i>Blood</i> , 2016, 128, 637-637.	0.6	48
126	Letter From the Editor: I love boobies. <i>Clinical Advances in Hematology and Oncology</i> , 2016, 14, 72.	0.3	0



#	ARTICLE	IF	CITATIONS
127	Letter From the Editor: Doctors as writers. <i>Clinical Advances in Hematology and Oncology</i> , 2016, 14, 143.	0.3	0
128	Letter From the Editor: Moonshot medicine. <i>Clinical Advances in Hematology and Oncology</i> , 2016, 14, 198.	0.3	0
129	Letter From the Editor: The pedant and the scoundrel. <i>Clinical Advances in Hematology and Oncology</i> , 2016, 14, 286.	0.3	0
130	Letter From the Editor: When Breath Becomes Air. <i>Clinical Advances in Hematology and Oncology</i> , 2016, 14, 382.	0.3	0
131	Letter From the Editor: When will we ever learn?. <i>Clinical Advances in Hematology and Oncology</i> , 2016, 14, 461.	0.3	0
132	Letter from the editor: the campaign button. <i>Clinical Advances in Hematology and Oncology</i> , 2016, 14, 566.	0.3	0
133	Letter From the Editor: From 2003 to today. <i>Clinical Advances in Hematology and Oncology</i> , 2016, 14, 646.	0.3	0
134	Letter From the Editor: Fellowship interviews and more. <i>Clinical Advances in Hematology and Oncology</i> , 2016, 14, 742.	0.3	1
135	Letter From the Editor: Ode to Bob. <i>Clinical Advances in Hematology and Oncology</i> , 2016, 14, 838.	0.3	0
136	Letter From the Editor: The end. <i>Clinical Advances in Hematology and Oncology</i> , 2016, 14, 942.	0.3	0
137	Evaluation of the International Prognostic Score (IPS <sup>7</sup> ) and a Simpler Prognostic Score (IPS <sup>3</sup> ) for advanced Hodgkin lymphoma in the modern era. <i>British Journal of Haematology</i> , 2015, 171, 530-538.	1.2	54
138	Rethinking Clinical Response and Outcome Assessment in a Biologic Age. <i>Current Oncology Reports</i> , 2015, 17, 27.	1.8	3
139	Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 1221-1223.	0.8	3
140	Reply to G. Keramida et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 4121-4122.	0.8	1
141	Advances in the treatment of follicular lymphoma. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 207-218.	0.5	0
142	Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. <i>Journal of Clinical Oncology</i> , 2015, 33, 2399-2404.	0.8	97
143	Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1936-1942.	0.8	33
144	A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory lymphomas. <i>British Journal of Haematology</i> , 2015, 169, 528-533.	1.2	12

#	ARTICLE	IF	CITATIONS
145	What is the status of novel anti-CD20 antibodies for chronic lymphocytic leukemia and are they set to leave rituximab in the shadows?. Expert Review of Hematology, 2015, 8, 733-742.	1.0	9
146	Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). Journal of Clinical Oncology, 2015, 33, 3635-3640.	0.8	163
147	Ofatumumab and bendamustine in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma. Leukemia and Lymphoma, 2015, 56, 915-920.	0.6	29
148	Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501). Leukemia and Lymphoma, 2015, 56, 958-964.	0.6	36
149	Primary Results of the Health-Related Quality of Life Assessment from the Phase III Gadolin Study of Obinutuzumab Plus Bendamustine Compared with Bendamustine Alone in Patients with Rituximab-Refractory, Indolent Non-Hodgkin Lymphoma. Blood, 2015, 126, 1532-1532.	0.6	5
150	Phase II Trial of Ofatumumab (OFA) in Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL): CALGB 50901 (Alliance). Blood, 2015, 126, 2741-2741.	0.6	3
151	Interfollicular CD10 Expression and Follicular PD1 Tumor-Infiltrating Lymphocytes As Biologic Risk Factors in Patients with Previously Untreated Follicular Lymphoma Receiving Rituximab-Based Biologic Therapy: An Alliance Correlative Science Study (CALGB 50901, 50402, 50701, 50803, 50401). Blood, 2015, 126, 334-334.	0.6	2
152	Bortezomib Maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): CALGB (Alliance) 50403. Blood, 2015, 126, 337-337.	0.6	23
153	Analysis of Minimal Residual Disease in Follicular Lymphoma Patients in Gadolin, a Phase III Study of Obinutuzumab Plus Bendamustine Versus Bendamustine in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. Blood, 2015, 126, 3978-3978.	0.6	17
154	Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma (Alliance 051103). Blood, 2015, 126, 471-471.	0.6	15
155	Pre-Transplant R-Bendamustine Induces High Rates of Minimal Residual Disease in MCL Patients: Updated Results of S1106: US Intergroup Study of a Randomized Phase II Trial of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplants for Patients with Mantle Cell Lymphoma. Blood, 2015, 126, 518-518.	0.6	5
156	Initial Results of US Intergroup Trial of Response-Adapted Chemotherapy or Chemotherapy/Radiation Therapy Based on PET for Non-Bulky Stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604). Blood, 2015, 126, 578-578.	0.6	21
157	Favorable Outcomes in CLL Pts with Alternate Kinase Inhibitors Following Ibrutinib or Idelalisib Discontinuation: Results from a Large Multi-Center Study. Blood, 2015, 126, 719-719.	0.6	10
158	Two doses of polatuzumab vedotin (PoV, anti-CD79b antibody-drug conjugate) in patients (pts) with relapsed/refractory (RR) follicular lymphoma (FL): Durable responses at lower dose level.. Journal of Clinical Oncology, 2015, 33, 8503-8503.	0.8	15
159	GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma.. Journal of Clinical Oncology, 2015, 33, LBA8502-LBA8502.	0.8	10
160	Staging and response assessment in lymphomas: the new Lugano classification. Chinese Clinical Oncology, 2015, 4, 5.	0.4	99
161	GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma.. Journal of Clinical Oncology, 2015, 33, LBA8502-LBA8502.	0.8	2
162	Long-Term Outcomes, Secondary Malignancies, and Stem Cell Collection Following Bendamustine in Patients with Previously Treated Indolent Non-Hodgkin Lymphoma. Blood, 2015, 126, 3961-3961.	0.6	0

#	ARTICLE	IF	CITATIONS
163	Patterns of Lymphocytosis in Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Treated with Idelalisib. <i>Blood</i> , 2015, 126, 2952-2952.	0.6	0
164	The creative destruction of medicine. <i>Clinical Advances in Hematology and Oncology</i> , 2015, 13, 12.	0.3	5
165	Letter From the Editor: Lies and truth. <i>Clinical Advances in Hematology and Oncology</i> , 2015, 13, 140.	0.3	0
166	Letter From the Editor: Inside my file cabinets. <i>Clinical Advances in Hematology and Oncology</i> , 2015, 13, 203.	0.3	0
167	Letter From the Editor: The return of the emperor. <i>Clinical Advances in Hematology and Oncology</i> , 2015, 13, 271.	0.3	0
168	The "ASC(ST)O" meeting. <i>Clinical Advances in Hematology and Oncology</i> , 2015, 13, 341.	0.3	0
169	Letter From the Editor: Reflections on Lugano. <i>Clinical Advances in Hematology and Oncology</i> , 2015, 13, 409.	0.3	0
170	Letter From the Editor: Interviewing season. <i>Clinical Advances in Hematology and Oncology</i> , 2015, 13, 621.	0.3	0
171	Letter From the Editor: For what it's worth. <i>Clinical Advances in Hematology and Oncology</i> , 2015, 13, 695.	0.3	0
172	Letter From the Editor: A thankful end of the year. <i>Clinical Advances in Hematology and Oncology</i> , 2015, 13, 787.	0.3	0
173	Lymphoma: looking from the present to the future. <i>Chinese Clinical Oncology</i> , 2015, 4, 2.	0.4	21
174	Bendamustine: role and evidence in lymphoma therapy, an overview. <i>Leukemia and Lymphoma</i> , 2014, 55, 1471-1478.	0.6	19
175	A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. <i>Journal of Hematology and Oncology</i> , 2014, 7, 44.	6.9	76
176	Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2014, 370, 997-1007.	13.9	1,535
177	Current role of FDG PET/CT in lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1004-1027.	3.3	63
178	Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10A002. <i>British Journal of Haematology</i> , 2014, 165, 102-111.	1.2	78
179	PET-CT restaging: a surrogate for follicular lymphoma?. <i>Lancet Haematology</i> , the, 2014, 1, e2-e3.	2.2	2
180	Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. <i>Journal of Clinical Oncology</i> , 2014, 32, 3059-3067.	0.8	3,729

#	ARTICLE	IF	CITATIONS
181	CALGB 150905 (Alliance): Rituximab Broadens the Antilymphoma Response by Activating Unlicensed NK Cells. <i>Cancer Immunology Research</i> , 2014, 2, 878-889.	1.6	48
182	A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: Correlation between clinical responses and AUC pharmacokinetics. <i>Clinical Immunology</i> , 2014, 154, 37-46.	1.4	25
183	Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. <i>Journal of Clinical Oncology</i> , 2014, 32, 3048-3058.	0.8	1,269
184	Which Hodgkin's Patients in the United States Should Be Treated with BEACOPP?. <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 222-226.	1.2	2
185	Bendamustine in the treatment of chronic lymphocytic leukemia. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 617-623.	0.5	2
186	CLL and NHL: the end of chemotherapy?. <i>Blood</i> , 2014, 123, 3368-3370.	0.6	12
187	Unexpected and Serious Toxicity Observed with Combined Idelalisib, Lenalidomide and Rituximab in Relapsed/Refractory B Cell Lymphomas: Alliance A051201 and A051202. <i>Blood</i> , 2014, 124, 3091-3091.	0.6	28
188	Second Interim Analysis of a Phase 3 Study of Idelalisib (ZYDELIGÂ®) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient Subpopulations with Del(17p) and Other Adverse Prognostic Factors. <i>Blood</i> , 2014, 124, 330-330.	0.6	61
189	Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma. <i>Blood</i> , 2014, 124, 4457-4457.	0.6	26
190	Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7011-7011.	0.8	6
191	Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7012-7012.	0.8	11
192	Phase 2 trial of GS-9973, a selective syk inhibitor, and idelalisib (idela) in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2014, 32, 7059-7059.	0.8	9
193	Health-related quality of life (HRQL) impact of idelalisib (IDELA) in patients (pts) with relapsed chronic lymphocytic leukemia (CLL): Phase 3 results.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7099-7099.	0.8	3
194	Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PIV) plus rituximab (RTX) in patients (Pts) with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8519-8519.	0.8	16
195	CALGB 50803 (Alliance): A phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8521-8521.	0.8	12
196	U.S. Intergroup phase II trial (SWOG 1108) of alisertib, an investigational aurora A kinase (AAK) inhibitor, in patients with peripheral T-cell lymphoma (PTCL; NCT01466881).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8523-8523.	0.8	4
197	Letter from the editor. <i>Clinical Advances in Hematology and Oncology</i> , 2014, 12, 76.	0.3	0
198	Letter from the editor. <i>Clinical Advances in Hematology and Oncology</i> , 2014, 12, 152.	0.3	0

#	ARTICLE	IF	CITATIONS
199	Burnout. <i>Clinical Advances in Hematology and Oncology</i> , 2014, 12, 208.	0.3	0
200	When I came to the National Cancer Institute. <i>Clinical Advances in Hematology and Oncology</i> , 2014, 12, 279.	0.3	0
201	Five Days At Memorial by Dr Sheri Fink. <i>Clinical Advances in Hematology and Oncology</i> , 2014, 12, 352.	0.3	0
202	Letter from the Editor. <i>Clinical Advances in Hematology and Oncology</i> , 2014, 12, 422.	0.3	0
203	Letter from the editor. <i>Clinical Advances in Hematology and Oncology</i> , 2014, 12, 496.	0.3	0
204	<i>Clinical Advances in Hematology &amp; Oncology</i> . Letter from the editor. <i>Clinical Advances in Hematology and Oncology</i> , 2014, 12, 558.	0.3	0
205	Highlights from the 2014 Congress of the European Hematology Association. <i>Clinical Advances in Hematology and Oncology</i> , 2014, 12, 619-22.	0.3	0
206	The interviewing of the fellows. <i>Clinical Advances in Hematology and Oncology</i> , 2014, 12, 636.	0.3	0
207	Is ebola scarier than cancer?. <i>Clinical Advances in Hematology and Oncology</i> , 2014, 12, 718.	0.3	0
208	Assisted suicide for patients with terminal illness. <i>Clinical Advances in Hematology and Oncology</i> , 2014, 12, 797.	0.3	0
209	BEACOPP or no BEACOPP?. <i>Lancet Oncology, The</i> , 2013, 14, e487-e488.	5.1	9
210	Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: CALGB 50202 (Alliance 50202). <i>Journal of Clinical Oncology</i> , 2013, 31, 3061-3068.	0.8	408
211	Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus <sup>131</sup> Iodine-Tositumomab for Previously Untreated Follicular Non-Hodgkin Lymphoma: SWOG S0016. <i>Journal of Clinical Oncology</i> , 2013, 31, 314-320.	0.8	152
212	Therapy for diffuse large B-cell lymphoma: getting personal. <i>Lancet, The</i> , 2013, 381, 1793-1794.	6.3	6
213	The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance). <i>Leukemia and Lymphoma</i> , 2013, 54, 1405-1410.	0.6	27
214	State-of-the-Art Research on “Lymphomas: Role of Molecular Imaging for Staging, Prognostic Evaluation, and Treatment Response”. <i>Frontiers in Oncology</i> , 2013, 3, 212.	1.3	31
215	A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. <i>Cancer</i> , 2013, 119, 3797-3804.	2.0	47
216	A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP+Rituximab versus CHOP + <sup>131</sup> Iodine-Tositumomab. <i>Clinical Cancer Research</i> , 2013, 19, 6624-6632.	3.2	32

#	ARTICLE	IF	CITATIONS
217	Safety Profile and Clinical Response To MEDI-551, a Humanized Monoclonal Anti-CD19, In a Phase 1/2 Study In Adults With Relapsed Or Refractory Advanced B-Cell Malignancies. <i>Blood</i> , 2013, 122, 1810-1810.	0.6	14
218	The Utility Of 18f-FDG PET/CT In Assessing Bone Marrow Involvement In Lymphoma. <i>Blood</i> , 2013, 122, 2981-2981.	0.6	2
219	Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance). <i>Blood</i> , 2013, 122, 3002-3002.	0.6	2
220	The Role Of Body Mass Index In Survival Outcome For Lymphoma Patients: US Intergroup Experience. <i>Blood</i> , 2013, 122, 3060-3060.	0.6	5
221	Evaluation Of a Novel 3 Factor Prognostic Score (PS-3) For Patients With Advanced Hodgkin Lymphoma (HL) Treated On US Intergroup E2496. <i>Blood</i> , 2013, 122, 4277-4277.	0.6	3
222	Final Results Of a Phase I Study Of The Anti-CD22 Antibody-Drug Conjugate (ADC) DCDT2980S With Or Without Rituximab (RTX) In Patients (Pts) With Relapsed Or Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL). <i>Blood</i> , 2013, 122, 4399-4399.	0.6	10
223	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2013, 122, LBA-6-LBA-6.	0.6	4
224	MEDI-551, an anti-CD19 antibody active in chronic lymphocytic leukemia (CLL) patients previously treated with rituximab.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7045-7045.	0.8	2
225	Improved Risk Stratification With Addition Of Male Sex (S) To The Elderly International Prognostic Index (S-EIPI) For DLBCL Patients > 60 Years Treated With R-CHOP: An International Collaboration Of The US Intergroup, German High-Grade Non-Hodgkin Lymphoma Study Group and Groupe d'Etude De Lymphome Adultes. <i>Blood</i> , 2013, 122, 3045-3045.	0.6	2
226	Safe and effective treatment of aggressive non-hodgkin lymphoma with rituximab and bendamustine in patients with severe liver impairment. <i>Clinical Advances in Hematology and Oncology</i> , 2013, 11, 184-8.	0.3	10
227	Atheists don't have no songs. <i>Clinical Advances in Hematology and Oncology</i> , 2013, 11, 332.	0.3	0
228	Complete response to brentuximab vedotin in a transplant-naïve patient with relapsed CD30-positive nodular lymphocyte-predominant Hodgkin lymphoma. <i>Clinical Advances in Hematology and Oncology</i> , 2013, 11, 382-5.	0.3	2
229	Letter from the editor. <i>Clinical Advances in Hematology and Oncology</i> , 2013, 11, 759.	0.3	0
230	Letter from the editor. <i>Clinical Advances in Hematology and Oncology</i> , 2013, 11, 692.	0.3	0
231	A summer of change in hematologic malignancies: highlights in B-Cell malignancies from the 2013 ASCO, EHA, and ICML meetings. <i>Clinical Advances in Hematology and Oncology</i> , 2013, 11, 748-50.	0.3	0
232	The potential for eliminating chemotherapy in indolent non-Hodgkin lymphoma. <i>Clinical Advances in Hematology and Oncology</i> , 2013, 11 Suppl 14, 5-8.	0.3	1
233	Interim [ <sup>18</sup> F]fluorodeoxyglucose positron emission tomography imaging in stage II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?. <i>Leukemia and Lymphoma</i> , 2012, 53, 2143-2150.	0.6	54
234	Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 2183-2189.	0.8	1,332

#	ARTICLE	IF	CITATIONS
235	Hodgkin Lymphoma: Protecting the Victims of Our Success. <i>Journal of Clinical Oncology</i> , 2012, 30, 4456-4457.	0.8	20
236	Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 2820-2822.	0.8	182
237	A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. <i>Haematologica</i> , 2012, 97, 758-765.	1.7	153
238	A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma. <i>Cancer</i> , 2012, 118, 3128-3134.	2.0	95
239	Results of a Phase 1 Dose-Escalation Study of Once-Weekly MLN9708, an Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma. <i>Blood</i> , 2012, 120, 3646-3646.	0.6	3
240	MEDI-551, a Humanized Monoclonal Anti-CD19, in Adults with Relapsed or Refractory Advanced B-Cell Malignancies: Results From a Phase 1/2 Study. <i>Blood</i> , 2012, 120, 3677-3677.	0.6	5
241	Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant. <i>Blood</i> , 2012, 120, 3701-3701.	0.6	7
242	A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL). <i>Blood</i> , 2012, 120, 59-59.	0.6	7
243	CALGB 50401: A randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 8000-8000.	0.8	16
244	Phase I/II study of MEDI-551, a humanized monoclonal antibody targeting CD19, in subjects with relapsed or refractory advanced B-cell malignancies. <i>Journal of Clinical Oncology</i> , 2012, 30, 8065-8065.	0.8	1
245	A phase III randomized intergroup trial (S0016) comparing CHOP plus rituximab with CHOP plus iodine-131-tositumomab for front-line treatment of follicular lymphoma: Results of subset analyses and a comparison of prognostic models. <i>Journal of Clinical Oncology</i> , 2012, 30, 8001-8001.	0.8	1
246	Lenalidomide Following Rituximab and Fludarabine in Untreated CLL. <i>Blood</i> , 2012, 120, 3924-3924.	0.6	0
247	Cell of Origin in Richter's Transformation of CLL. <i>Blood</i> , 2012, 120, 4574-4574.	0.6	2
248	Differences in Outcomes in Males and Females with Diffuse Large B-Cell Lymphoma with Induction Rituximab and Follicular Lymphoma Treated with Maintenance Rituximab. <i>Blood</i> , 2012, 120, 3705-3705.	0.6	0
249	BCL6 Expression and Treatment Delay Correlate with Adverse Outcome in Newly Diagnosed Primary CNS Lymphoma: Final Report of CALGB 50202 (Alliance). <i>Blood</i> , 2012, 120, 301-301.	0.6	0
250	Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 3389-3395.	0.8	104
251	Role of Functional Imaging in the Management of Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1844-1854.	0.8	251
252	New agents in follicular lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 305-312.	0.7	10

#	ARTICLE	IF	CITATIONS
253	Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. <i>Blood</i> , 2011, 117, 5314-5320.	0.6	56
254	Time To Remember To Forget Dose-Intensification in Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 3954-3956.	0.8	5
255	Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trial. <i>Future Oncology</i> , 2011, 7, 9-14.	1.1	4
256	Genetic abnormalities in CLL: prognostic factors—or their own disease?. <i>Oncology</i> , 2011, 25, 706, 708.	0.4	0
257	Accurate reporting of adverse events in chronic lymphocytic leukemia and non-Hodgkin lymphoma. <i>Clinical Advances in Hematology and Oncology</i> , 2011, 9, 1-11.	0.3	0
258	Bendamustine: mechanism of action and clinical data. <i>Clinical Advances in Hematology and Oncology</i> , 2011, 9, 1-11.	0.3	9
259	Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. <i>Cancer</i> , 2010, 116, 106-114.	2.0	217
260	Author reply: Rituximab maintenance for follicular lymphoma. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 1-1.	12.5	0
261	Syk [sic] of the same old chemotherapy?. <i>Blood</i> , 2010, 115, 2561-2562.	0.6	2
262	Response: Defining response criteria in CLL patients treated in clinical research trials. <i>Blood</i> , 2010, 116, 1817-1818.	0.6	1
263	Targeted treatment and new agents in follicular lymphoma. <i>International Journal of Hematology</i> , 2010, 92, 5-11.	0.7	7
264	The 51st Annual Meeting of the American Society of Hematology. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 11-20.	0.2	1
265	Optimal Use of Bendamustine in Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphomas, and Multiple Myeloma: Treatment Recommendations From an International Consensus Panel. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 21-27.	0.2	83
266	The Sarcoid-Lymphoma Syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 241-247.	0.2	31
267	Bendamustine Produces Durable Responses With an Acceptable Safety Profile in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 452-457.	0.2	50
268	Bendamustine in chronic lymphocytic leukemia and non-Hodgkin's lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1353-1365.	1.1	8
269	Ofatumumab, a Novel Anti-CD20 Monoclonal Antibody for the Treatment of B-Cell Malignancies. <i>Journal of Clinical Oncology</i> , 2010, 28, 3525-3530.	0.8	154
270	Monoclonal antibody therapy of chronic lymphocytic leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2010, 23, 133-143.	0.7	16



#	ARTICLE	IF	CITATIONS
271	Combination Biologic Therapy as Initial Treatment for Follicular Lymphoma: Initial Results From CALGB 50701 - a Phase II Trial of Extended Induction Epratuzumab (anti-CD22) and Rituximab (anti-CD20). <i>Blood</i> , 2010, 116, 427-427.	0.6	10
272	R-CHOP Versus (vs) CHOP Followed by Maintenance Rituximab (MR) Vs Observation In Older Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Long-Term Follow-up of Intergroup E4494/C9793. <i>Blood</i> , 2010, 116, 589-589.	0.6	7
273	Intensive Chemotherapy and Immunotherapy, without Brain Irradiation, In Newly Diagnosed Patients with Primary CNS Lymphoma: Results of CALGB 50202. <i>Blood</i> , 2010, 116, 763-763.	0.6	4
274	Letter from the editor. <i>Clinical Advances in Hematology and Oncology</i> , 2010, 8, 144.	0.3	0
275	The Case Against Heavy PETing. <i>Journal of Clinical Oncology</i> , 2009, 27, 1742-1743.	0.8	43
276	Bendamustine: Rebirth of an Old Drug. <i>Journal of Clinical Oncology</i> , 2009, 27, 1492-1501.	0.8	237
277	Novel therapies for peripheral T-cell non-Hodgkin's lymphomas. <i>Current Opinion in Hematology</i> , 2009, 16, 299-305.	1.2	20
278	Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. <i>Blood</i> , 2009, 113, 299-305.	0.6	260
279	Bendamustine Produces Durable Responses with An Acceptable Long-Term Safety Profile in Patients with Rituximab-Refractory Non-Hodgkin's Lymphoma: A Pooled Analysis.. <i>Blood</i> , 2009, 114, 2681-2681.	0.6	5
280	Lenalidomide Alone and in Combination with Rituximab Enhances NK Cell Immune Synapse Formation in Chronic Lymphocytic Leukemia (CLL) Cells in Vitro through Activation of Rho and Rac1 GTPases.. <i>Blood</i> , 2009, 114, 3441-3441.	0.6	6
281	A Phase I Study of PRO131921, a Novel Anti-CD20 Monoclonal Antibody in Patients with Relapsed/Refractory CD20+ Indolent NHL: Correlation Between Clinical Responses and AUC Pharmacokinetics.. <i>Blood</i> , 2009, 114, 3742-3742.	0.6	8
282	Etiology and management of tumor lysis syndrome in patients with chronic lymphocytic leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2009, 7, 263-71.	0.3	14
283	Bendamustine induced neurotoxicity. <i>Clinical Advances in Hematology and Oncology</i> , 2009, 7, 743-6.	0.3	13
284	Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2008, 359, 613-626.	13.9	412
285	Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B. <i>British Journal of Haematology</i> , 2008, 140, 313-319.	1.2	26
286	Staging and Evaluation of the Patient with Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2008, 22, 825-837.	0.9	25
287	Meeting Highlights. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, 210-218.	1.4	0
288	Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 4473-4479.	0.8	333

#	ARTICLE	IF	CITATIONS
289	Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 204-210.	0.8	271
290	Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute's Working Group 1996 guidelines. <i>Blood</i> , 2008, 111, 5446-5456.	0.6	2,887
291	New Staging and Response Criteria for Non-Hodgkin Lymphoma and Hodgkin Lymphoma. <i>Radiologic Clinics of North America</i> , 2008, 46, 213-223.	0.9	30
292	Lenalidomide for the Treatment of B-Cell Malignancies. <i>Journal of Clinical Oncology</i> , 2008, 26, 1544-1552.	0.8	169
293	A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies. <i>Clinical Cancer Research</i> , 2008, 14, 8295-8301.	3.2	183
294	Needle tract seeding after bone marrow biopsy in non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 156-158.	0.6	17
295	FLIPI Score Is Applicable and Predictive of Response to Upfront Immunotherapy in CALGB 50402: Phase II Trial of Extended Induction Galiximab ([G] anti-CD80 monoclonal antibody) Plus Rituximab [R]. <i>Blood</i> , 2008, 112, 1003-1003.	0.6	4
296	Phase I Dose-Escalation Trial of BI 2536, a Polo-Like Kinase 1 Inhibitor, in Relapsed and Refractory Non-Hodgkin's Lymphoma. <i>Blood</i> , 2008, 112, 233-233.	0.6	6
297	Ghostwriting. <i>Clinical Advances in Hematology and Oncology</i> , 2008, 6, 318.	0.3	0
298	Bendamustine: a new therapeutic option for hematologic malignancies. <i>Clinical Advances in Hematology and Oncology</i> , 2008, 6, 631-3.	0.3	1
299	Adult Burkitt lymphoma: too soon to declare victory. <i>Oncology</i> , 2008, 22, 1518-9.	0.4	0
300	Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 571-578.	0.8	1,275
301	The role of FDG-PET scans in patients with lymphoma. <i>Blood</i> , 2007, 110, 3507-3516.	0.6	285
302	Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901. <i>Leukemia and Lymphoma</i> , 2007, 48, 97-103.	0.6	39
303	Overcoming mechanisms of RESISTance in lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 447-448.	0.6	2
304	Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: Cancer and leukemia Group B protocol 50206. <i>Leukemia and Lymphoma</i> , 2007, 48, 1313-1319.	0.6	64
305	Revised Response Criteria for Malignant Lymphoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 579-586.	0.8	4,061
306	The International Harmonization Project for Response Criteria in Lymphoma Clinical Trials. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 841-854.	0.9	115

#	ARTICLE	IF	CITATIONS
307	Clinical Management of T-Cell Malignancies: Current Perspectives, Key Issues, and Emerging Therapies. <i>Seminars in Oncology</i> , 2007, 34, S3-S7.	0.8	10
308	Is BEACOPP better than ABVD?. <i>Current Hematologic Malignancy Reports</i> , 2007, 2, 161-166.	1.2	8
309	Bendamustine Is Safe and Effective in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma.. <i>Blood</i> , 2007, 110, 1351-1351.	0.6	6
310	A Phase I Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor Obatoclax Mesylate (GX15-070) Administered by Continuous Infusion for up to Four Days to Patients with Hematological Malignancies.. <i>Blood</i> , 2007, 110, 892-892.	0.6	6
311	Oblimersen for the treatment of patients with chronic lymphocytic leukemia. <i>Therapeutics and Clinical Risk Management</i> , 2007, 3, 855-70.	0.9	32
312	Emerging treatments for indolent lymphoma. <i>Clinical Advances in Hematology and Oncology</i> , 2007, 5, 1-9; quiz 11-2.	0.3	2
313	Positron-Emission Tomography and Assessment of Cancer Therapy. <i>New England Journal of Medicine</i> , 2006, 354, 496-507.	13.9	685
314	Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. <i>Blood</i> , 2006, 108, 419-425.	0.6	1,395
315	Radioimmunotherapy of Non-Hodgkins Lymphomas. <i>Current Drug Targets</i> , 2006, 7, 1293-1300.	1.0	24
316	Monoclonal antibody therapy of chronic lymphocytic leukemia. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 188-196.	2.0	44
317	Monoclonal Antibody Therapy for B-Cell Malignancies. <i>Seminars in Oncology</i> , 2006, 33, 2-14.	0.8	43
318	The Cancer and Leukemia Group B Lymphoma Committee. <i>Clinical Cancer Research</i> , 2006, 12, 3572s-3575s.	3.2	1
319	Phase II Results of Bendamustine in Combination with Rituximab in Relapsed Indolent and Mantle-Cell Non-Hodgkin's Lymphoma.. <i>Blood</i> , 2006, 108, 2710-2710.	0.6	6
320	Immuno-Chemotherapy (IC) and Autologous Stem Cell Transplant (ASCT) for Untreated Patients (pts) with Mantle Cell Lymphoma (MCL): CALGB 59909.. <i>Blood</i> , 2006, 108, 2737-2737.	0.6	3
321	The Impact of GM-CSF on Arsenic Trioxide (As2O3, Trisenox) Therapy in Patients with Myelodysplastic Syndrome (MDS): Preliminary Results of a Phase II Study.. <i>Blood</i> , 2006, 108, 4856-4856.	0.6	1
322	CLL response criteria. <i>Clinical Advances in Hematology and Oncology</i> , 2006, 4, 4-5; discussion 10; suppl 12.	0.3	0
323	Role of Positron Emission Tomography in Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 4577-4580.	0.8	108
324	Response Assessment of Aggressive Non-Hodgkin's Lymphoma by Integrated International Workshop Criteria and Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography. <i>Journal of Clinical Oncology</i> , 2005, 23, 4652-4661.	0.8	364

#	ARTICLE	IF	CITATIONS
325	The Role of Radioimmunotherapy with Yttrium-90 Ibritumomab Tiuxetan in the Treatment of Non-Hodgkin Lymphoma. <i>BioDrugs</i> , 2005, 19, 309-322.	2.2	17
326	The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development. <i>Clinical Cancer Research</i> , 2005, 11, 7967-7985.	3.2	219
327	Revised Response Criteria for Malignant Lymphomas From the Members of the International Harmonization Project (IHP) of the Competence Network Malignant Lymphoma, Represented by... <i>Blood</i> , 2005, 106, 18-18.	0.6	12
328	A Phase I Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor GX15-070 Administered Intravenously (IV) Every 3 Weeks to Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2005, 106, 446-446.	0.6	15
329	Development of a Measure of Health-Related Quality of Life for Non-Hodgkinâ€™s Lymphoma Clinical Research: The Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym).. <i>Blood</i> , 2005, 106, 750-750.	0.6	21
330	SGN-30 (Anti-CD30 Monoclonal Antibody) Is Active and Well Tolerated in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma (ALCL).. <i>Blood</i> , 2005, 106, 3356-3356.	0.6	1
331	Flow Cytometric Analysis in Myelodysplastic Syndrome (MDS).. <i>Blood</i> , 2005, 106, 4932-4932.	0.6	0
332	Treatment Outcomes in Patients (Pts) with Transformed Chronic Lymphocytic Leukemia (CLL) in One Institution.. <i>Blood</i> , 2005, 106, 5031-5031.	0.6	0
333	Managing malignancy-associated hyperuricemia with rasburicase. <i>The Journal of Supportive Oncology</i> , 2005, 3, 117-24.	2.3	10
334	Phase II Study of SGN-30 (Anti-CD30 Monoclonal Antibody) in Patients with Refractory or Recurrent Hodgkinâ€™s Disease.. <i>Blood</i> , 2004, 104, 2635-2635.	0.6	39
335	Phase II Study of Thalidomide in Escalating Doses for Follicular (F-NHL) and Small Lymphocytic Lymphoma (SLL): CALGB Study 50002.. <i>Blood</i> , 2004, 104, 3284-3284.	0.6	5
336	Deletion of 13q14 Is Independent of CD38 Expression in Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2004, 104, 4807-4807.	0.6	0
337	ZAP-70 Expression in Chronic Lymphocytic Leukemia (CLL) Is Independent of Rai Stage: A Retrospective Review of 38 Patients (pts).. <i>Blood</i> , 2004, 104, 4811-4811.	0.6	0
338	Overview of the revised response criteria for acute myelogenous leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2004, 2, 277-9.	0.3	4
339	Radioimmunotherapy of non-Hodgkin lymphomas. <i>Blood</i> , 2003, 101, 391-398.	0.6	165
340	Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2003, 21, 4642-4649.	0.8	2,425
341	Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. <i>Blood</i> , 2002, 99, 2685-2693.	0.6	292
342	Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. <i>Blood</i> , 2002, 100, 2260-2262.	0.6	83

#	ARTICLE	IF	CITATIONS
343	Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. <i>Blood</i> , 2002, 100, 2260-2.	0.6	18
344	Some Like It Hot!. <i>Journal of Clinical Oncology</i> , 2001, 19, 3908-3911.	0.8	23
345	Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2000, 343, 1750-1757.	13.9	939
346	Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas. <i>Journal of Clinical Oncology</i> , 1999, 17, 1244-1244.	0.8	3,209
347	Superiority of Tandem Autologous Transplantation Over Standard Therapy for Previously Untreated Multiple Myeloma. <i>Blood</i> , 1997, 89, 789-793.	0.6	520
348	International staging and response criteria for lymphomas. , 0, , 277-285.		0